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Author Response 
We are grateful to Asadi-Pooya and Martinez-Lapiscina et al for their thoughtful responses to our 
paper. We believe they raise important considerations for developing the work to deliver better 
neuroprotection for persons with multiple sclerosis. 
We used phenytoin to inhibit voltage-gated sodium channels. Asadi-Pooya suggests that a drug with 
a better side effect profile and fewer drug interactions would be preferable. While these are 
attributes of an ideal drug, we stress that this was a proof of concept study in which the overriding 
requirement was for a sodium channel inhibitor which could be loaded to achieve therapeutic 
concentrations within hours. Our positive findings should encourage development of an alternative 
to phenytoin which (unlike presently available alternatives) can be loaded quickly, and which is 
better tolerated. Importantly, they reinforce the emerging concept of a narrow window of 
opportunity for sodium channel inhibition to provide neuroprotection as an attack of multiple 
sclerosis begins1. 
Asadi-Pooya and Martinez-Lapiscina et al both comment that treatment had no significant effect on 
vision. We stress again that this was a proof of concept study without the statistical power to 
evaluate clinical benefit. Using a biomarker of neurodegeneration (thickness of the retinal nerve 
fibre layer, RNFL) for the primary outcome enabled a realistic sample size. Lack of power meant that 
we did not dwell on the results of colour vision and low contrast acuity (LCVA), which were actually 
better (albeit non-significantly) in the group treated with phenytoin. To establish significance, we 
calculate that the effect size on LCVA we found in our study (0.15 for 2.5% LCVA vs 0.45 for the 
RNFL) would require a trial involving 630 participants, underlining the need to identify a more 
sensitive, meaningful vision outcome for future work2. However, we would urge caution in using the 
binary outcome suggested by Martinez-Lapiscina et al: i)  the clinical meaningfulness of their 7-letter 
cutoff of inter eye asymmetry of LCVA remains unproven3; ii) the relationship between loss of vision 
and tissue atrophy depends on threshold effects and is unlikely to be linear4; iii) outcomes should be 
adjusted for measurements at baseline, whereas their proposed outcome involves measurement of 
vision post-treatment in the unaffected eye, which is vulnerable both to treatment effects and to 
intercurrent optic neuritis in that eye; and iv) regardless of any correlation between inter eye 
asymmetry of vision and atrophy of the RNFL, a binary outcome of the kind they suggest cannot 
demonstrate a between-group difference with greater statistical power than an adjusted 
comparison of the continuous variable upon which the binary dichotomy is based5. Binary 
classifications are useful for distinguishing ‘normal’ from ‘abnormal’ in a clinical setting, but they are 
less powerful and often unnecessary in trial settings.  However, for interest, we report the results 
using the suggested binary measure on our data: the proportions of subjects with 6-month 
unaffected LCVA >7 more than 6-month affected are: active 64% (25/39) vs placebo 71% (30/42), 
p=0.480 for 1.25% LCVA, and active 62% (24/39) vs placebo 74% (31/42), p=0.237 for 2.5%.   
Finally, Martinez-Lapiscina et al refer to possible methodological limitations of our study6, mostly to 
do with the use of the RNFL to measure outcome, rather than the ganglion cell plus inner plexiform 
(GCIP) layers, in turn requiring us to measure the unaffected eye for baseline adjustment. There are 
advantages in comparing the GCIP measurements in the same eye, and we welcome further work in 
which this outcome is assessed prospectively. However, cellular heterogeneity of the GCIP, 
especially after optic neuritis7, may limit the interpretation of changes of its thickness, and in our 
preliminary comparison, adjusted changes in the RNFL remained more sensitive to treatment 
effects8.  
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